A Little Bit of History
=======================

Two centuries have passed since James Parkinson's *Essay on the Shaking Palsy* described a handful of patients who showed tremor at rest, bradykinesia and, some of them, akinesia. In his essay, he characterized the motor symptoms of the disease that now takes his name ([@B105]). Although this was the first description of the disease as a neurological condition, it was not until 50 years later that new scientific evidence obtained by Jean-Martin Charcot contributed to a definition of the clinical and anatomopathological basis of Parkinson's Disease (PD) ([@B23]). Years later, in 1893, Blocq and Marinescu noticed resting tremor in a patient that resembled parkinsonian symptoms. The tremor was due to a tuberculous granuloma on the right cerebral peduncle that was affecting the ipsilateral *Substantia nigra pars compacta* (SNc) ([@B9]). It was Brissaud a few years later who suggested that the SNc might be the site affected in PD ([@B15]). Two decades later, Trétiakoff first reported neuropathological changes in the SNc in PD patients. He observed a large loss of neuromelanin in the SNc resulting from the absence of SNc neurons containing this pigment and also the presence of cytoplasmatic inclusions named Lewy bodies (LB) ([@B144]). These structures had been described some years earlier by James Lewy and, from that moment onward, this feature of PD became the focal point of neuropathological studies on PD ([@B84]). The presence of both loss of dopaminergic neurons in the SNc and LB was established as the anatomopathological hallmark and diagnostic criterion of PD ([@B111]).

At this point, the diagnostic criteria were established, but the main challenge was to assure successful treatment. The first neurosurgery of the basal ganglia (BG) to treat PD took place in 1940. Between the late 1950s and the mid-1960s many discoveries were made about the existence of dopamine (DA) as a neurotransmitter ([@B97]; [@B22]) and its role in the striatum ([@B6]; [@B20]; [@B122]). In 1957, Carlsson reported the first evidence for a functional role for DA, describing the reserpine effect in reducing motor activity in animals, which was reversed by L-3,4-dihydroxyphenylalanine (L-DOPA) administration, a precursor in DA synthesis. DA signaling proved to play a crucial role in motor control by the BG ([@B21]). Soon after this, evidence emerged of the striatal DA deficiency in PD ([@B121]). Particularly, Ehringer and Hornykiewicz described a deficit in both the striatum and the SNc in brains from parkinsonian patients ([@B39]). Furthermore, some studies sustained the presence of a dopaminergic nigrostriatal projections and they also revealed that the dorsolateral striatum mainly receives terminals from SNc neurons. It happens that this area of the striatum is the most affected in PD ([@B32]; [@B2]). After these discoveries, the L-DOPA era began. During these years, it was demonstrated that intravenous injection of L-DOPA and also small oral doses of L-DOPA in humans had anti parkinsonian effects ([@B29]). From that moment L-DOPA became the gold-standard treatment for PD, since many authors consistently reported a marked improvement in PD with large oral doses of L-DOPA ([@B63]). Since then significant progress has been made in the development of new pharmacological and surgical tools to treat PD motor symptoms ([@B134]).

A new important breakthrough took place in 1983 when Langston and colleagues reported a group of drug users who developed acute parkinsonism after MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) exposure ([@B80]). These patients developed an acute syndrome indistinguishable from PD. This is due because the MPTP metabolite, MPP+, destroys the dopaminergic neurons in the substantia nigra after a series of alterations in the mitochondrial matrix and the electron transport chain. The SNc of Parkinson patients was also described as exhibiting a marked decrease in complex I activity ([@B33]; [@B124]). The fact that some PD patients have certain polymorphisms in genes that express subunits of complex I suggests that this could be a vulnerability factor in PD ([@B75]; [@B147]). New models based on MPTP intoxication allowed researchers to ascertain PD hallmarks both *in vitro* and *in vivo* ([@B79]). Due to the achievements of pharmacological DA treatments, search of cell-based DA replacement approaches were initiated with largely disappointing results ([@B4]). From the surgical and therapeutic point of view, discrete lesions of the BG improved parkinsonism ([@B95]). A monkey model of PD showed motor signs improvement as a result of the chemical destruction of the subthalamic nucleus (STN) ([@B5]), with evidence of reversal of experimental parkinsonism by STN lesions. This same year deep brain stimulation (DBS) of the STN became effective for PD treatment ([@B56]; [@B116]; [@B34]).

In the late 1990s, due to the improvement and sophistication of genetic analysis techniques, mutations in *SNCA* gene codifying for alpha-synuclein (α-syn) protein were identified as the first genetic cause of PD ([@B109]). Once it was clear that *SNCA* mutations cause parkinsonism, and more than 80 years after the discovery of LB, α-syn protein was found to be the main component of LB ([@B136], [@B135]). Later on and based on these discoveries, [@B13] proposed a pathological staging of the disease. From that time on, genetic studies have revealed many other mutations in other genes related to PD (*PINK1, LRRK2, Parkin, DJ1*, etc... see *Advances in genetics* below). The discovery of different genetic variants affecting the risk of PD has provided the field with a new battery of potential therapies ready to be tested in clinical trials. The initial findings have been followed by intensive research and the identification of several genes linked to PD pathogenesis in the last few years. Developments in genetics and molecular techniques such as CRISPR, have allowed the raise of new experimental models based on the use of transgenic animals presenting mutations associated to PD ([@B145]). These examples open the door to studies where using genetic-based animal models would allow to assess the potential role of α-syn aggregation and spreading, evaluating potential therapeutics, imaging tracers or biomarkers ([@B35]; [@B74]; [@B73]; [@B90]); also, the cellular models offer unique opportunities for the identification of therapeutic strategies capable of modulating the disease ([@B81]). These new models join the well-known classic neurotoxin based animal models such as MPTP or 6-OHDA that have provided a valuable insight into potential new targets for disease intervention ([@B7]; [@B98]).

At present, catching theories linking alterations in the gut microbiota to PD of the disease open new research areas in the hunt of the etiology of the disease ([@B119]). Many efforts are concentrated in decoding the pre-symptomatic phases and turning scientific progresses into disease-modifying therapies for PD ([@B8]). In this sense, exciting cutting-edge approaches with less invasive technologies such as gamma knife or focused ultrasound for the treatment of motor symptoms in PD have been advanced ([@B92]) (see *New technologies for the diagnosis, clinical assessment and treatment of Parkinson's Disease* below) (Figure [1](#F1){ref-type="fig"}).
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Advances in Genetics
====================

The etiology of PD remains largely unknown. The majority of patients are classified as idiopathic PD cases, i.e., arising 'spontaneously' or from an unknown cause. Prevalence is estimated at 1% in people above 65 years and increases exponentially in subsequent decades of life ([@B42]) and in fact, aging is considered the major known risk factor. Yet, continuous and intense efforts have been undertaken to improve our incomplete comprehension of the disease. In this context, genetic research has played a pivotal role in elucidating the cause of disease, most especially during the last 20 years. Earlier than that, the genetic contribution to PD was unrecognized because classic reports of PD familial clustering or twin concordance studies were scarce and controversial ([@B43]). It was in 1997 when a linkage study first identified unequivocal familial segregation of the missense mutation A53T in the *SNCA* gene with an adult-onset autosomal-dominant PD phenotype ([@B109]). Subsequently, other pathogenic missense mutations in *SNCA* were identified including A30P, E46K, H50Q, G51N, and A53T ([@B77]; [@B158]; [@B82]; [@B113]). In 1998, another pioneer study reported that the α-synuclein protein was the main component of the proteinaceous aggregates termed Lewy bodies and Lewy neurites which are found in the soma and neurites of the few surviving dopaminergic neurons of the SNpc in PD patients ([@B136], [@B135]). The identification of *SNCA* led to a shift of paradigm in the classification of PD patients into monogenic or familial PD (fPD) cases caused by pathogenic mutations in genes associated with the disease (5--10% of cases), and the vast majority of patients encompassing sporadic PD (sPD) cases (95%). The identification of SNCA was also seminal to set the basis for the subsequent intense genetic cell and animal modeling of the disease in the lab ([@B132]; [@B24]; [@B66]). More recently, multiplications of the *SNCA* locus, duplications and triplications, were found to cause PD with an inverse correlation between gene dose and age-at-onset, but a direct effect on disease severity ([@B24]; [@B66]; [@B133]). Overall mutations in *SNCA* are uncommon in frequency and lead to a DOPA-responsive early-onset parkinsonism, often severe and with dementia that is pathologically characterized by nigral neurodegeneration and widespread brainstem and cortical LB pathology.

Until date, a total of 23 loci and 19 causative genes have been associated with PD, yet with certain degree of heterogeneity regarding phenotypes (PD only or PD plus syndromes), age-at-onset (juvenile or adult onset), and inheritance mode (autosomal dominant, recessive or X-linked) (Table [1](#T1){ref-type="table"}). Whereas some of the genes associated to the *PARK* loci have not been yet identified (*PARK3, PARK10, PARK12*, and *PARK16*), the pathogenicity of a few PD-associated genes still remains controversial due to novelty or to lack of replication of the original study (*UCHL1, GIGYF2, EIF4G1, SYNJ1, TMEM230*, and *CHCHD2*). Yet, mutations in the remaining genes, although rare in frequency, have been unequivocally established as PD-causative and account for the majority of autosomal dominant (*SNCA*, *LRRK2*, *HTRA2*, and *VPS35*) or recessive PD cases (*PRKN*, *PINK1*, *DJ-1, ATP13A2, PLA2G6, FBXO7, DNAJC6*, and *VPS13C*). Among the dominant genes, the identification by linkage analysis of mutations in the leucine-rich repeat gene (*LRRK2*) in some PD families with adult onset autosomal-dominant inheritance simultaneously by two groups ([@B103]; [@B163]) represented another major milestone in PD research. Subsequently, three different groups identified in parallel the mutation G2019S at the kinase domain of LRRK2 as the most common pathogenic variant of *LRRK2-*associated PD ([@B37]; [@B59]; [@B69]) that remarkably it is found not only in monogenic but also in sPD cases lacking mendelian segregation. The *LRRK2*-associated PD form uniquely resembles common sPD at the clinical and neuropathological levels, yet with slight clinical differences ([@B91]; [@B110]), and eventual pleomorphic pathology ([@B163]). Of note, the penetrance of G2019S mutation is limited but rises progressively with age ([@B57]; [@B89]) and has been shown to be modified by additional factors such as genetic risk polymorphisms and other still unknown factors ([@B146]; [@B46]). Moreover, mutations in HtrA Serine Peptidase 2 (*HTRA2*) ([@B138]) and vesicle protein sorting 35 (*VPS35*) ([@B148]; [@B162]) are responsible of typical L-DOPA responsive PD, although no neuropathological data is not available yet. On the other hand, mutations in the recessive genes including parkin (*PRKN*), PTEN-induced putative kinase 1 (*PINK1*) and *DJ-1* are causative of early-onset parkinsonism shearing largely identical clinical phenotypes, but distinct neuropathology. *PRKN*-associated PD is characterized by pure degeneration in the *SNc* and *locus coeruleus* without LB pathology and occasional Tau inclusions ([@B126]), whereas *PINK1* mutations lead to nigral neurodegeneration with LB and neurites ([@B118]), and *DJ1*-associated pathology includes severe degeneration in the SNc and *locus coeruleus* with diffuse LBs and axonal spheroids ([@B139]). In addition, pathogenic mutations in the genes ATPase 13A2 (*ATP13A2*) ([@B14]), phospholipase A2 (*PLA2G6*) ([@B52]) F-Box protein 7 (*FBXO7*) ([@B128]), DNA J Heat Shock Protein Family (Hsp40) Member C6 (*DNAJC6*) ([@B38]) and Vacuolar Protein Sorting 13 Homolog C (*VPS13C*) ([@B83]) are linked to autosomal recessive, early-onset atypical parkinsonism that often comprises additional clinical features such as pyramidal degeneration, ataxia or dementia, with or without LBs. Overall, although the relative contribution of pathogenic mendelian genes to overall PD is limited, genetic research in PD has been instrumental since it has uniquely permitted the identification of disease molecular alterations, pathophysiological pathways, and candidate therapeutic targets, most of which are believed to be largely common to sPD. Thus genetic findings in PD have undoubtly paved the way out for tackling overall pathology of all PD cases.

###### 

Summary of genes associated with Parkinson's disease.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *Locus*     Gene        Inheritance                Onset   Location     Variants                                                               Function
  ----------- ----------- -------------------------- ------- ------------ ---------------------------------------------------------------------- -------------------------------------------------
  *PARK1/4*   *SNCA*      Dominant\                  EO      4q21.3-q22   5 point mutations, multiplications Rep1 risk variant in the promoter   Synaptic vesicles trafficking
                          Risk factor                                                                                                            

  *PARK2*     *PARKIN*    Recessive                  EO      6q25.2-q27   \>250 point mutation, ins/de and exon rearrangements                   Mitophagy

  *PARK3*     Unknown     Dominant                   LO      2p13         ?                                                                      ?

  *PARK5*     *UCHL1*     Dominant                   LO      4p13         1 missense variant in one sibling pair                                 Proteasome

  *PARK6*     *PINK1*     Recessive                  EO      1p36.12      \>100 point mutations, ins/del and exon rearrangements                 Mitophagy

  *PARK7*     *DJ-1*      Recessive                  EO      1p36.23      \>20 point mutations and deletions                                     Mitophagy

  *PARK8*     *LRRK2*     Dominant                   LO      12q12        7 point mutations                                                      Autophagy?

                          Risk factor                                     Risk variants p.R1628P and p.G2385R                                    

  *PARK9*     *ATP13A2*   Recessive                  EO      1p36         \>20 point mutations                                                   Lysosomes

  *PARK10*    Unknown     Risk factor                ?       1p32         ?                                                                      ?

  *PARK11*    *GIGYF2*    Recessive                  EO      2q36-7       7 missense variants                                                    Insulin-like growth factors (IGFs) signaling

  *PARK12*    Unknown     Risk factor                ?       Xq21-q22     ?                                                                      ?

  *PARK13*    *HTRA2*     Dominant                   ?       2p13.1       1 missense variant                                                     Mitophagy,

  *PARK14*    *PLA2G6*    Recessive                  EO      22q13.1      \>18 missense variants                                                 Lipids metabolism

  *PARK15*    *FBXO7*     Recessive                  EO      22q12.3      4 point mutations                                                      Mitophagy

  *PARK16*    Unknown     Risk factor                ?       1q32         ?                                                                      ?

  *PARK17*    *VPS35*     Dominant                   LO      16q12        2 point mutations                                                      Endosomes

  *PARK18*    *EIF4G1*    Dominant                   LO      3q27.1       1 missense variant                                                     Protein translation

  *PARK19*    *DNAJC6*    Recessive                  EO      1p31.3       9 missense variants                                                    Endosomes

  *PARK20*    *SYNJ1*     Recessive                  EC      21q22.11     3 missense variants                                                    Endosomes

  *PARK21*    *DNAJC13*   Dominant                   LO      3q22.1       1 missense variant                                                     Endosomes

  *PARK22*    *CHCHD2*    Dominant                   LO/EO   7p11.2       1 missense variant, 1 truncation                                       Mitochondria-mediated apoptosis and metabolism?

  *PARK23*    *VPS13C*    Recessive                  EO      15q22.2      2 missense variants,l truncation                                       Mitophagy

  --          *GBA*       AD, AR in GD Risk factor   LO      lq22         \>10 missense variants                                                 Lysosomes

  --          *MAPT*      Sporadic\                          17q21.31     H1 haplotype increase PD risk and disease severity                     Microtubules
                          Risk factor                                                                                                            

                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EO, early onset; LO, late onset.

In addition to PD-causative mutations, classical candidate gene association approaches or more recently large genome-wide association studies (GWAS) have identified common genetic variants in genes such as *SNCA*, *LRRK2*, microtubule-associated protein tau gene (*MAPT*) or glucosylceramidase beta (*GBA*) which contribute to increase PD susceptibility ([@B86]). The variants in *MAPT* ([@B106]; [@B51]; [@B18]) and *SNCA* ([@B12]; [@B19]; [@B16]) loci showed the strongest association with PD risk across populations and most importantly, also at the GWAS level ([@B131]; [@B11]; [@B99]) correlating not only with higher risk but with increased disease age-at-onset as well ([@B151]). On the other hand, common variants in LRRK2 increase the risk of PD only in Asian populations but not in Europeans ([@B44]; [@B87]). In addition, mutations in *GBA* which codifies the lysosomal enzyme β-glucocerebrosidase are causative of the recessive lysosomal storage disorder Gaucher's disease. Both homozygous and heterozygous *GBA* variants increase the risk of developing PD ([@B140]). Moreover, *GBA*-mutation carriers show a more severe parkinsonism than idiopathic patients, earlier age-at-onset and more frequently dementia ([@B140]). Besides genetics, epigenetic alterations have also been suggested to play a role in the pathogenesis of PD in recent years. Thus, abnormal changes in various epigenetic mechanisms regulating gene expression such as DNA methylation ([@B93]; [@B30]; [@B45]; [@B107]), histones modifications ([@B104]) or microRNAs (miRNAs) ([@B72]) have been linked to disease, thus opening a new venue of epigenetic research in PD.

From Motor to Non-Motor Symptoms
================================

Motor disturbances in PD have been widely investigated leading to a better diagnosis and origination of validated rating scales and therapies. However, the non-motor symptoms (NMS) of PD also have major importance when evaluating the quality of life of patients and the impact on health economics, attracting a growing interest in the last years. The incidence of NMS augments along with the disease duration, even preceding the motor symptoms or signs by several years. Symptoms such as olfactory dysfunction, REM sleep behavior disorder (RBD), constipation, depression, and pain ([@B25]; [@B143]) appear to be clear indicators of a preclinical phase of the disease. This concept is reinforced by studies showing an augmented risk for patients with idiopathic RBD or idiopathic hyposmia to develop a synucleinopathy ([@B10]; [@B67]; [@B117]; [@B112]).

In early phases of the disease, some of these NMS still remain in many patients. Up to 21% of patients report pain, depression or anxiety ([@B102]). Importantly, in many cases, patients report a major disturbances of these NMS rather than motor ones, in the beginning of the disease ([@B54]; [@B108]).

We currently know that PD involves disorders in several neurotransmitters pathways, including the cholinergic, noradrenergic, and serotonergic systems ([@B156]; [@B55]; [@B68]; [@B17]). This fact could relate symptoms such as depression with the loss of dopaminergic and noradrenergic transmission in the limbic system; and also anxiety and apathy, associated in this case to the low dopaminergic transmission ([@B141]). On the other hand, excess of dopaminergic transmission due to DA agonist therapy, can prompt some NMS. Impulse control disorders (ICDs) is one of the most common side effects of dopamine replacement therapy used in PD with an estimated prevalence of 4.9--19% ([@B149]; [@B154]). ICDs are behavioral addictions including exaggerated behaviors such as gambling or shopping related to the administration of D2/D3 agonists. Research on this topic remains quite reduced and preclinical studies are limited because of the lack of alternatives for the pharmacological treatment. ([@B149]). It seems that the fact that in PD-ICD patients there is a major denervation in the ventral striatum this leads to an "over-dose" when dopamine is administered in ventral areas and limbic pathways ([@B153]; [@B150]). Nevertheless, further studies should be performed in order to achieve a better comprehension of the disorder and the development of successful treatments.

Non-motor fluctuations (uncomfortable anxiety, slowness of thinking, fatigue, and dysphoria) are other psychiatric disorder also DA-dependent, and reported primarily during "OFF" periods and can be reversed with continuous dopaminergic replacement ([@B26]).

Nowadays, NMS denote some of the most relevant sources of disability and impairment in quality of life of parkinsonian patients and the acknowledgment of these symptoms become critical for the improvement and advances in the diagnosis of the disease ([@B25]). Still, in many cases, NMS of PD are not distinguished in routine clinical evaluations since their origin are not directly related to PD ([@B129]).

These circumstances indicate the relevance of developing successful tools to identify NMS, both for the assessment and for their treatment ([@B53]). The development of valuable instruments capable of supporting neurologists at the time of diagnosis would also mean a benefit for the rise of valid therapeutic strategies ([@B127]) (see *Diagnosis and clinical assessment devices* below). This is reflected in the scarce therapies available for non-motor deficits ([@B159]). Currently, dopaminergic treatments are the most broadly used therapies, but they have no impact on those aspects of the disease that are associated to other neurotransmitter deficits. Conversely, the use of anticholinergics, for example, classically increases the cognitive symptoms of PD, as it does deep brain stimulation surgery ([@B155]).

To sum up, the increasing prevalence of non-motor complications is far complex marking a new concept in the scenery of PD. These problems are linked with a marked decrease of quality of life of the patients and the social life of their families. Their etiology is multifaceted and still poorly understood. Thus, specific NMS treatments are required, as current treatment options for NMS in PD continue incomplete and large areas remain unfulfilled of therapeutic need.

New Technologies for the Diagnosis, Clinical Assessment and Treatment of Parkinson's Disease
============================================================================================

In the last decade, new technology-based tools and technology-based therapies have been advanced with the objective of refining the diagnosis, clinical assessment and treatment of patients with movement disorders. The development and intricacy of molecular and cellular techniques, as well as extraordinary progress in technology, have marked a milestone in our general understanding of the disease.

Drug Delivery Systems
---------------------

The clinical use of neuroprotective molecules has been hampered by several issues, and among these, drug delivery to the brain remains a particular challenge. To address these limitations, drug delivery systems and methods that allow enhanced brain delivery of neuroprotective molecules have been investigated. These new technologies offer unprecedented advantages enabling protection of sensitive molecules from degradation and controlled release over days or months. Drug delivery systems can also be engineered to target diseased regions within the body, thereby enhancing the specificity of therapeutics. Therefore, the delivery and efficacy of many pharmaceutical compounds can be improved and their side effects reduced. Among drug delivery systems, microparticles (MPs), nanoparticles (NPs) and hydrogels (HGs) seem to be the most effective in providing neuroprotection, although liposomes and micelles have also been investigated (Figure [2](#F2){ref-type="fig"}) ([@B50]; [@B114]). MPs and NPs are particulate carrier systems in the micrometer and nanometer size range, respectively. MPs are generally used for the long-term delivery of drugs while NPs are commonly used as carriers of small molecules for targeted and intracellular delivery. On the other hand, HGs are tridimensional polymeric networks that absorb a large amount of water, which becomes their principal component. Formulations can be designed either for local administration into the brain or for systemic delivery to achieve targeted action in the central nervous system. The examples below show that drug delivery systems are in the initial stages of the drug development process, but the potential for using this technology for PD treatment is very high.
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Drug Delivery Systems for Neurotrophic Factor Therapy
-----------------------------------------------------

Neurotrophic factors, and glial cell line-derived neurotrophic factor (GDNF) in particular, have been regarded as one of the most promising molecules for PD. In this regard, several delivery systems have been designed focused on increasing GDNF stability and retention in the brain. Several studies have demonstrated the preclinical efficacy of microencapsulated GDNF in different PD animal models (rodents and monkeys) ([@B50], [@B49], [@B48]). In those studies, a single injection of microencapsulated GDNF achieved long term improvement of motor function and dopaminergic function restoration in parkinsonian monkeys with severe nigrostriatal degeneration. The injectable formulation localized GDNF within the putamen and prevented systemic off-target effects. GDNF showed trophic effects on the nigrostriatal pathway increasing striatal and nigral dopaminergic neurons. Moreover, microencapsulated GDNF did not elicit immunogenicity or cerebellar degeneration. This example demonstrates that MPs are an efficient vehicle for sustained GDNF delivery to the brain. In another approach, vascular endothelial growth factor (VEGF), a potent angiogenic factor with prosurvival effects in neuronal cultures, was combined with GDNF to enhance the action of the latter ([@B62]). A pronounced tyrosine hydroxylase (TH) neuron recovery was observed in the SNc of parkinsonian rats. Later, a combinatorial strategy of NPs-containing GDNF and VEGF was locally applied in a partially lesioned rat PD model. Behavioral improvement was observed together with a significant enhancement of dopaminergic neurons both in the striatum and SNc, which corroborates previous work in GDNF and VEGF encapsulation. Interestingly, the synergistic effect of the therapeutic proteins allows dose reduction while still providing neurogenerative/neuroreparative effects ([@B60]). The direct nose to brain administration of GDNF-NPs is another promising trend. One of the most recent examples uses nanoencapsulated GDNF in lipid NPs ([@B61]). In order to enhance the target NP delivery to the brain, the nanocarrier surface was modified with a cell-penetrating peptide named TAT. The formulation improved the nose to brain delivery of GDNF, thereby improving motor function recovery and GDNF neuroprotective effects when tested in a mouse PD model. An alternative approach to NPs is the use of liposomes. Uptake of the neurotrophic factor to the brain via intranasal delivery is enhanced when GDNF is encapsulated in a liposomal formulation ([@B96]). In order to move forward with nose to brain delivery strategies greater formulation retention in the olfactory region needs to be achieved, together with better targeting of specific brain regions. Finally, another promising approach that has been undertaken for GDNF brain delivery is the use of nanoformulations able to cross the blood brain barrier through receptor-mediated-delivery. This strategy would allow non-invasive drug delivery to the brain. Based on this concept, neuroprotection has been observed after the intravenous administration of a GDNF nanoformulation ([@B65]). The NPs improved locomotor activity, reduced dopaminergic neuronal loss and enhanced monoamine neurotransmitter levels in parkinsonian rats. A remaining challenge is to target specific brain areas in order to avoid unwanted side effects.

Besides GDNF, other neurotrophic factor such as basic fibroblast growth factor (bFGF) have been evaluated. One example involves gelatin nanostructured lipid carriers encapsulating bFGF that can be targeted to the brain via nasal administration ([@B160]). Overall, the nanoformulation stimulated dopaminergic function in surviving synapses and played a neuroprotective role in 6-OHDA hemiparkinsonian rats. A very recent study took advantage of the neuroprotective properties of Activin B, which was administered in a parkinsonian mice using a thermosensitive injectable HG ([@B85]). The biomaterial allowed a sustained protein release over 5 weeks and contributed to substantial cellular protection and behavioral improvement.

Drug Delivery Systems for Stem Cell Therapy
-------------------------------------------

In recent years, stem cells have attracted considerable attention as regards achieving neuroprotection. However, cell therapy has been limited by the low engraftment of the administered cells. By applying a combination of biomaterials, cells and bioactive molecules, brain repair can be facilitated. In an early example, MPs loaded with neurotrophin-3 were used to retain injected adult stem cells in the striatum and to support cell viability and differentiation ([@B36]). When tested in a PD rat model, a potent behavioral recovery was observed together with nigrostriatal pathway protection/repair. Going a step further, BDNF-loaded MPs have been encapsulated in a HG embedded with mesenchymal stem cells for neural differentiation and secretome enhancement ([@B70]). This strategy not only provides neuroprotective BDNF but also stem cells that benefit from that environment by displaying neural commitment and an improved neuroprotective/reparative secretome. Likewise, HGs have also been used to improve dopaminergic progenitor survival and integration after transplantation. A report by T. Wang and co-workers pioneered the development of a composite scaffold made of nanofibers embedded within a xyloglucan HG. The biomaterial was further functionalized with GDNF to improve the niche surrounding the implanted cells ([@B152]). The scaffold enhanced graft survival and striatal re-innervation. A similar strategy was followed by Adil MM, that determined the impact of a heparin/RGD functionalized hyaluronic acid HG on the survival of embryonic stem cell-derived dopaminergic neurons ([@B1]). These examples demonstrate the potential of biologically functionalized HGs to improve stem cell delivery. Beyond HGs, the use of NPs as a tool to optimize MSC therapeutics was underlined in a recent study by T. Chung and coworkers that successfully developed a dextran-coated iron oxide nanosystem to improve the rescuing effect of mesenchymal stem cells ([@B28]).

In addition to stem cell delivery, biomaterials can also be used to deliver mesenchymal stem cell secretome at the site of injury. By way of example, adipose mesenchymal stem cell secretome has been encapsulated in a biodegradable injectable HG that was able to increase the controlled release of the neuroprotective factors in a PD-relevant experimental context ([@B27]). NPs can also be used to modulate the subventricular neurogenic niche and boost endogenous brain repair mechanisms using microRNAs. Due to the short half-life and poor stability of these molecules, their efficient delivery into cells is a challenge. NPs can provide a shielded environment and controlled release. One example involves microRNA-124, a potent pro-neurogenic factor for neural stem cells which has been nanoencapsulated, demonstrating the feasibility of this approach as well as its efficacy in parkinsonian mice ([@B123]). The nanoformulation promoted not only neurogenesis but also the migration and maturation of new neurons in the lesioned striatum. Specifically, this example illustrates the potential of nanotechnology for improving not only the safety and efficacy of conventional drugs, but also the delivery of newer drugs based on microRNAs to the brain. Overall, these promising results suggest that biomaterials and drug delivery systems are a valid alternative to enhance stem cell neuroprotective properties. Further studies are needed for the advancement of this technology from preclinical studies to clinical trials.

Nanomedicines for Antioxidant Delivery
--------------------------------------

Mitochondrial damage and oxidative stress have been proposed as the major contributing factors to PD pathogenesis. Accordingly, coenzyme Q10 has been considered a promising molecule in PD management due to its ability to enhance mitochondrial function. However, its efficacy has been hindered by insolubility, poor bioavailability and lack of brain penetration. In order to solve these issues, a nanomicellar coenzyme Q10 formulation able to stop, but not reverse, ongoing neurodegeneration has shown efficacy in a mouse PD model ([@B130]). Moreover, this neuroprotective treatment activates an astrocytic reaction suggesting that these cells played a significant role in neuron protection. In addition to coenzyme Q10, curcumin counteracts oxidative stress and mitochondrial dysfunction. However, its clinical efficacy has been limited by its poor aqueous solubility, rapid metabolism and inadequate tissue absorption. Piperine has been used as adjuvant to improve curcumin's bioavailability. Thus, curcumin and piperine amalgamation seems beneficial. Moreover, nanomedicines could also help to enhance drug transport from blood to the brain. In one example, both therapeutics were loaded in a lipid-based nanoformulation blended with different surfactants and orally administered in a PD mouse model ([@B78]). A higher density of nigral TH^+^ neurons was found in the animals treated with dual drug loaded NPs, demonstrating that the system was able to cross the blood brain barrier preventing dopaminergic neuronal degeneration. This may be due to the improved curcumine bioavailability and the synergistic effect exhibited by both drugs. Another strategy to detain oxidative stress and achieve neuroprotection is the use of nanoencapsulated resveratrol ([@B31]). The nanoformulation was able to attenuate MPTP-induced lipid peroxidation and prevent striatal TH protein decrease in parkinsonian mice. These findings suggest that resveratrol-loaded NPs are a promising nanomedical tool for PD.

Nanomedicines That Interfere With α-syn Expression
--------------------------------------------------

Strategies that interfere with α-syn expression in neurons have also received widespread attention. One remarkable approach is the targeted gene therapy proposed by [@B100] that has provided effective repair in a PD mice model using magnetic NPs loaded with shRNA plasmid for α-syn. Multifunctional magnetic NPs were effectively delivered through the blood brain barrier, prevented DA neuron degeneration as reflected by TH up-regulation and α-syn down-regulation and inhibited further apoptosis in the brain. Alternatively, suppression of α-syn overexpression has been demonstrated using gold NPs which could load plasmid DNA, cross the blood--brain barrier and target specific cells. For example, the group of Y. Guan achieved successful results in carrying pDNA into the neurons, and thus inhibiting dopaminergic neuron apoptosis ([@B64]). These approaches have the potential to suppress α-syn expression, providing a highly efficient treatment for PD.

Focused Ultrasound
------------------

In the last few years, the use of focused ultrasound (FUS) therapies has been revolutionizing the treatment of neurological disorders. This non-invasive technique consists in the application of focused acoustic energy (ultrasound) on selected brain areas. The MR-guided FUS (MRgFUS) allowed computer calculated targeting and achieved high accuracy with real-time feedback on the effect of the treatment. The first studies using MRgFUS thalamotomy in patients with essential tremor showed a significant clinical reduction in hand tremor ([@B40]). In PD, MRgFUS is being explored as a way to non-invasively ablate the brain areas responsible for the motor features associated with the disease. In 2014, MRgFUS of the pallidothalamic tract was used in PD patients for the first time, with a significant clinical improvement ([@B88]). Subsequent studies using MRgFUS in the ventral intermediate thalamic nuclei (Vim) reported a clinically significant reduction in mean UPDRS scores post procedure in PD patients ([@B125]). In a recent pilot study, MRgFUS unilateral subthalamotomy was reported to be well tolerated and to improve the motor features of noticeably asymmetric PD patients ([@B92]). The questions of the best target for treating PD symptoms and whether different targets should be chosen for different patients are currently unresolved. Other unanswered questions are the long-term durability of FUS ablation outcomes and the safety and feasibility of bilateral procedures. The possibility of this non-invasive approach, with its immediate and apparently permanent clinical outcome, makes this treatment suitable for an increasing number of patients who are either unable or unwilling to undergo DBS therapy. Large randomized controlled trials are necessary to validate these preliminary findings and to assess the potential use of ablative FUS therapy in the treatment of PD patients. Other applications of FUS that are under current research are the opening of the brain--blood barrier (BBB) or neuromodulation ([@B76]). Low-Intensity Ultrasound decreased α-syn in PC12 cells ([@B71]). And more recently, using a non-invasive approach by combining MRgFUS and intravenous microbubbles and a shRNA sequence targeting α-syn, immunoreactivity of this protein have been decreased in several regions such as hippocampus, SNpc, olfactory bulb, and dorsal motor nucleus ([@B157]). This technology could be useful in the near future to alter the progression of LB pathology in combination with improved early diagnosis of the disease.

Deep Brain Stimulation
----------------------

Device-aided therapies, as levodopa--carbidopa infusion gel (LCIG), subcutaneous apomorphine pump infusion and deep brain stimulation (DBS), are essential tools in the treatment of advanced PD patients. During the last decade, evidence has been obtained regardless of safety, validity and efficacy in large prospective clinical studies ([@B3]).

Deep brain stimulation is a surgical therapy that involves the implantation of one or more electrodes in specific regions of the brain. There is substantial and consistent evidence indicating that DBS of both STN and GPi improve motor fluctuations, dyskinesia and quality of life in advanced PD ([@B115]; [@B47]). Those benefits are maintained for more than 10 years ([@B161]). Additionally, DBS treatment has been evaluated in patients with relatively short disease duration providing better motor outcomes and quality of life compared to the control group receiving best medical treatment ([@B142]).

Deep brain stimulation has notably improved due to the development of new neurosurgery approaches (asleep surgery), devices (microelectrodes, directional electrodes), and programming and stimulation algorithms. Particularly relevant is the implementation of the directional electrodes, which leads to a segmented stimulation. They provide a more accurate therapeutic frame and potentially reduce the adverse effects related to DBS ([@B137]).

The control of fluctuations could be improved and the adverse effects of DBS could be reduced by selective stimulation in a short-time window by using adaptive DBS (aDBS). Thus, aDBS is intended to personalize stimulation by recording local field potentials (LFP) directly from the stimulating electrode, which can only be activated when the LFP beta power exceeds a customized threshold. Therefore, it can modulate the stimulations according to the changes in the LFP beta power. aDBS seems to be more effective than conventional DBS in improving motor scores and controlling levodopa-induced dyskinesias. Further research over more extended time periods and larger cohorts are needed to ensure the benefit and efficacy of this novel strategy ([@B94]).

Diagnosis and Clinical Assessment Devices
-----------------------------------------

The use of new technology-based tools allows quantitative assessment of the motor function of PD patients. Sensors, video-assessment methods or mobile phone applications are some of the techniques that improve the sensitivity, accuracy and reproducibility of the evaluation of PD patients ([@B41]). Portable devices that include inertial measurement units (IMUs) measure the orientation, amplitude and frequency of movement, as well as the speed of the part of the body where they are located. IMUs are usually made up of accelerometers and gyroscopes, and occasionally magnetometers. IMUs situated in different parts of the patient's body make a precise record of tremor, bradykinesia, dyskinesias and even gait patterns ([@B58]). On the other hand, continual monitoring of the motor status in the domestic environment (regarding baseline motor status, motor fluctuations, and benefit of treatment, among other factors) is also possible by using these technology-based tools ([@B101]). These new technology-based systems open up an unexpected range of specific and real-time data, thereby resulting in the prospect of (1) better diagnostic accuracy, (2) more sensitive monitoring of the motor and non-motor symptoms, and (3) more precise adjustments of medical therapies. However, their use is limited in routine clinical practice due to the heterogeneity of the studies, which limit the extrapolation of results, and the high cost of the devices ([@B120]).

Conclusion
==========

In the future, population aging in developed countries will increase the burden of neurodegenerative diseases. In the case of PD, where treatment of symptoms needs to be patient-customized, balancing the control of symptoms, drug dose, presence of side effects and patient's expectations, clinicians and researchers face a situation in which a synergy of medicine and research is urgently needed. In summary, 200 years after the publication of James Parkinson's essay, our understanding of the disease has made remarkable progress and is still advancing, generating a considerable array of tools. Nowadays, fields such as functional genetics, novel molecular mechanisms, brain imaging and biomarker detection seem to be the major issues guiding our research strategies. Nevertheless, despite the progress made, improved early clinical diagnosis is still necessary and the disease lacks a cure. In this regard, research in drug delivery might provide safer and more effective treatments for PD. Years of research have revealed the need to take into account the role of environmental factors in addition to the genetics when studying PD progression. However, further research is needed to decipher the mechanisms by which this pathology spreads from cell to cell within the brain and from other organs to the central nervous system. Importantly, studies should also address early diagnosis (screening) tools, and more information is needed concerning the differential vulnerability of pathogenic factors affecting dopaminergic neurons.
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